Free Trial

Stock Traders Purchase High Volume of Soleno Therapeutics Put Options (NASDAQ:SLNO)

Soleno Therapeutics logo with Medical background

Soleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report) was the target of unusually large options trading activity on Tuesday. Stock traders bought 11,478 put options on the stock. This represents an increase of approximately 1,203% compared to the typical volume of 881 put options.

Insider Transactions at Soleno Therapeutics

In other news, insider Kristen Yen sold 3,108 shares of the company's stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $49.43, for a total transaction of $153,628.44. Following the completion of the transaction, the insider now owns 81,465 shares in the company, valued at approximately $4,026,814.95. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CFO James H. Mackaness sold 6,849 shares of the stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $45.77, for a total value of $313,478.73. Following the completion of the transaction, the chief financial officer now owns 148,914 shares in the company, valued at $6,815,793.78. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Kristen Yen sold 3,108 shares of the stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $49.43, for a total transaction of $153,628.44. Following the completion of the transaction, the insider now owns 81,465 shares of the company's stock, valued at $4,026,814.95. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 771,441 shares of company stock worth $37,178,033. Insiders own 12.30% of the company's stock.

Institutional Trading of Soleno Therapeutics

Hedge funds have recently made changes to their positions in the stock. Wellington Management Group LLP bought a new position in Soleno Therapeutics during the fourth quarter valued at approximately $8,557,000. Rafferty Asset Management LLC bought a new position in Soleno Therapeutics during the fourth quarter valued at approximately $2,088,000. Allspring Global Investments Holdings LLC bought a new position in Soleno Therapeutics during the first quarter valued at approximately $4,444,000. Price T Rowe Associates Inc. MD bought a new position in Soleno Therapeutics during the first quarter valued at approximately $6,533,000. Finally, Sofinnova Investments Inc. raised its position in Soleno Therapeutics by 267.7% during the second quarter. Sofinnova Investments Inc. now owns 554,359 shares of the company's stock valued at $22,618,000 after acquiring an additional 403,584 shares in the last quarter. 97.42% of the stock is owned by hedge funds and other institutional investors.

Soleno Therapeutics Trading Up 9.1 %

SLNO stock traded up $4.34 during mid-day trading on Tuesday, reaching $51.97. 4,529,486 shares of the stock traded hands, compared to its average volume of 449,725. Soleno Therapeutics has a 52-week low of $21.30 and a 52-week high of $56.56. The company has a market cap of $1.74 billion, a P/E ratio of -19.39 and a beta of -1.45. The stock's fifty day moving average is $48.89 and its 200-day moving average is $45.13.

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.57) EPS for the quarter, beating analysts' consensus estimates of ($0.63) by $0.06. Equities research analysts expect that Soleno Therapeutics will post -2.28 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on SLNO. Cantor Fitzgerald reiterated an "overweight" rating and issued a $67.00 target price on shares of Soleno Therapeutics in a research report on Friday, September 20th. Oppenheimer increased their target price on shares of Soleno Therapeutics from $59.00 to $65.00 and gave the company an "outperform" rating in a research report on Monday, August 12th. HC Wainwright initiated coverage on shares of Soleno Therapeutics in a research report on Tuesday, September 3rd. They set a "buy" rating and a $70.00 price objective for the company. Finally, Stifel Nicolaus raised their price objective on shares of Soleno Therapeutics from $59.00 to $74.00 and gave the company a "buy" rating in a research report on Tuesday, October 1st. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $68.71.

Read Our Latest Stock Analysis on Soleno Therapeutics

About Soleno Therapeutics

(Get Free Report)

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.

Read More

→ $5k to $1.3m in just 3 trades (From Insiders Exposed) (Ad)

Should you invest $1,000 in Soleno Therapeutics right now?

Before you consider Soleno Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Soleno Therapeutics wasn't on the list.

While Soleno Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in 2025 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Post-Election Chaos or Opportunity? Prepare Your Investments
Strong Markets Meet Rising Volatility—Are Your Investments Safe?
Analysts Bullish on AI-Powered Healthcare: Intuitive Surgical’s 30% Upside

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines